Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25555490 | 0.78 | NOS3 (0.33) | — | |
| SCHEMBL27863935 | 0.76 | AGBL2 (0.33) | AGBL2 | |
| SCHEMBL16491238 | 0.75 | HRH4 (0.33) | AGBL2HRH4 | |
| SCHEMBL19301653 | 0.74 | P2RX3 (0.38) | — | |
| SCHEMBL16386043 | 0.74 | AGBL2 (0.59) | AGBL2 | |
| SCHEMBL22842950 | 0.74 | AGBL2 (0.46) | AGBL2 | |
| SCHEMBL12190545 | 0.74 | AGBL2 (0.34) | AGBL2HRH4 | |
| SCHEMBL15159216 | 0.74 | ALOX5AP (0.32) | AGBL2HRH4 | |
| SCHEMBL23508963 | 0.72 | AGBL2 (0.41) | AGBL2 | |
| SCHEMBL12191685 | 0.72 | JAK2 (0.38) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11091486-B2 | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof | ARRAY BIOPHARMA, INC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20200216451-A1 | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | ARRAY BIOPHARMA, INC. | 2020-07-09 | — | — | US | disclosed |
| WO-2017147102-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | AGBL2 701/4885HRH4 2464/4885 |
| US-11091486-B2 | Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof | DPYD, TYMP, UMPS | AGBL2 4742/4885HRH4 3172/4885 |
| US-20200216451-A1 | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | DPYD, TYMP, UMPS | AGBL2 4742/4885HRH4 3172/4885 |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | AGBL2 701/4885HRH4 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.